Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Catecholamines in depression: an update

W Z Potter1, H K Manji

  • 1Section on Clinical Pharmacology, National Institute of Mental Health, Bethesda, MD 20892.

Clinical Chemistry
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

Schizophrenia research·2023
Same author

The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder.

Translational psychiatry·2017
Same author

The Role of Metabolites of Antidepressants in the Treatment of Depression.

CNS drugs·2016
Same author

Biomarkers of Brain Structure and Function for Neurodegenerative Disorders: Are They Adequate for Go/No Go Decisions in Drug Development?

Clinical pharmacology and therapeutics·2015
Same author

Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy.

International journal of psychiatry in clinical practice·2014
Same author

Rapid antidepressant effects: moving right along.

Molecular psychiatry·2013
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
Same journal

Editor's Note: Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer.

Clinical chemistry·2026
Same journal

In Reply to Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
See all related articles

Research indicates that depressed patients exhibit dysregulation of the noradrenergic system, with higher norepinephrine (NE) excretion and subsensitive responses to alpha 2-adrenergic agonists, suggesting a key role in affective disorders.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Psychiatry

Background:

  • Biochemical abnormalities in affective disorders are not fully understood.
  • The noradrenergic system is implicated in mood regulation.
  • Previous studies suggest noradrenergic system dysregulation in depression.

Purpose of the Study:

  • To investigate biochemical abnormalities in affective disorders.
  • To examine norepinephrine (NE) output and function in depressed patients.
  • To explore the role of the noradrenergic system in affective disorder pathogenesis.

Main Methods:

  • Biochemical assays to measure NE and normetanephrine excretion.
  • Neuroendocrine challenge strategies.
  • Measurement of peripheral blood cell receptors.

Related Experiment Videos

  • Assessing responses to alpha 2-adrenergic agonists.

    • Main Results:

    • Depressed patients, particularly melancholic unipolar subjects, excrete significantly more NE and normetanephrine than controls.
    • Depressed patients demonstrate subsensitive neuroendocrine (growth hormone) and biochemical (adenylate cyclase inhibition) responses to alpha 2-adrenergic agonists.
    • These findings suggest subsensitivity of nerve terminal alpha 2 autoreceptors.

    Conclusions:

    • The noradrenergic system is dysregulated in affective disorders.
    • Subsensitivity of alpha 2 autoreceptors may explain exaggerated plasma NE levels in depression.
    • Future research using brain imaging and molecular biology will enhance understanding of affective disorder pathophysiology.